

ELN FRONTIERS MEETING 2014

WHERE SCIENCE MEETS CLINICAL PRACTICE

16 – 19 OCTOBER 2014 | MARITIM HOTEL BERLIN, STAUFFENBERGSTRASSE | BERLIN, GERMANY

Chairs: Michele Baccarani
Rüdiger Hehlmann

Co-Chairs: Francisco Cervantes
François Guilhot
Wolf-Karsten Hofmann
Gert J. Ossenkoppele



CALL FOR ABSTRACTS

The Scientific Programme Committee invites you to submit abstracts for the **Poster Sessions** that will be held at the ELN Frontiers Meeting 2014.

We welcome all original research in the fields of chronic myeloid leukaemia (CML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).

The ELN will provide a travel subsidy and waive registration fees of the ELN Frontiers Meeting for the first author or designate of all accepted poster abstracts.

For further information contact the organiser:
SAN GmbH Science Agency & Network
Email: eln2014@sannet.ch

Submission deadline:
31 July 2014

For submission guidelines and on-line submission of abstracts go to:
www.sannet.ch/elnfrontiers2014



ELN FRONTIERS MEETING 2014

16 – 19 OCTOBER 2014 | MARITIM HOTEL BERLIN, STAUFFENBERGSTRASSE | BERLIN, GERMANY



Treatment discontinuation Diagnosis & classification
Minimal residual disease **MDS** Monitoring
Path to cure Disease biology
Long-term complete remission **Quality of life**
IFN- α Molecular pathogenesis JAK inhibitors
Variant translocations **AML**
CML Response Stem cell transplantation
Switch treatment to 2nd-line Targeted agents
Pre-clinical and clinical data **MPN** Cytogenetics
Prognosis Iron absorption, elimination, turnover
Long-term outcomes



3	WELCOME
4	AGENDA
8	FACULTY
10	STATEMENTS

WELCOME

Dear Colleague,

We are delighted to welcome you to the "ELN Frontiers Meeting 2014 – Where Science Meets Clinical Practice", in Berlin, Germany. This official meeting of the European LeukemiaNet (ELN) is supported by an unrestricted educational grant from Novartis Oncology and co-hosted by the ELN and the University of Heidelberg. An application for CPD has been lodged with the Federation of the Royal Colleges of Physicians, and CME approval is being sought through the European Accreditation Council for Continuing Medical Education.

The annual ELN Frontiers meetings are dedicated to discuss with European haematology fellows how clinical research has influenced haematology patient care, and how new research and clinical updates can be translated into new patient care strategies. Due to the success of previous years' meetings, the ELN Frontiers Meeting 2014 has been extended to a full 2.5 days. This has allowed us to provide an agenda with not only in depth reviews of recent advances in chronic myeloid leukaemia (CML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), but also allows sufficient time for valuable discourse with leading experts in these fields.

Exciting advances in TKI therapy and JAK inhibitors, improvements in understanding the importance of various cytogenetic abnormalities in MDS, and advances in management strategies for AML patients are must-know points for all of you who routinely treat leukaemic patients.

In addition to the academic reviews of CML, MPN, MDS and AML, the programme provides the opportunity to discuss best practice in clinical management and to ask clinically relevant questions in parallel Meet-the-Speaker and Case Discussion sessions. Be sure to attend the Research News sessions to gain top level insight into the forefront of research. The Oral Poster sessions will allow investigators to showcase their own research at this globally recognised event.

The ELN Frontiers Meeting builds upon 8 years of educational excellence in myeloid neoplasias. Please actively participate in this exciting congress with its rich mix of plenary and interactive sessions and variety of information transfer mediums.

Yours sincerely,



Rüdiger Hehlmann



Michele Baccarani

AGENDA

Thursday, 16th October 2014

19:30 – 22:00 Welcome dinner



Friday, 17th October 2014

MEETING OPENING		SESSION 3, RESEARCH NEWS	
08:30 – 09:00	Welcome and introduction	13:00 – 14:00	Parallel research news session (CML, MPN, AML, MDS)
SESSION 1, PLENARY – CML		14:00 – 14:20	Break and poster viewing
09:00 – 09:20	From genetic instability to blast crisis	SESSION 4, PLENARY – AML	
09:20 – 09:40	Factors influencing response & treatment recommendations	14:20 – 14:40	Current treatment of AML
09:40 – 10:00	The choice of first-line treatment	14:40 – 15:00	Treatment of APL
10:00 – 10:30	The choice of second-line treatment and beyond	15:00 – 15:20	Epigenetic treatment of AML (in elderly patients)
10:30 – 10:50	Treatment-free remission and path to cure	15:20 – 15:40	Post-remission treatment in AML
10:50 – 11:00	Break and poster viewing	15:40 – 16:00	Targeted therapy in AML
SESSION 2, MEET-THE-SPEAKERS – CML		16:00 – 16:30	Break and poster viewing
11:00 – 12:00	Parallel meet-the-speaker sessions	SESSION 5, MEET-THE-SPEAKERS – AML	
12:00 – 13:00	Lunch and poster viewing	16:30 – 17:30	Parallel meet-the-speaker sessions

Saturday, 18th October 2014

	KEYNOTE LECTURE		SESSION 3, CASE PRESENTATIONS
08:30 – 09:00	State of the art in stem cell transplantation	13:00 – 14:00	Parallel case presentation sessions (CML, MPN, AML, MDS)
	SESSION 1, PLENARY – MPN	14:00 – 14:20	Break and poster viewing
09:00 – 09:20	Ruxolitinib in MF. Current results		SESSION 4, PLENARY – MDS
09:20 – 09:40	Other JAK inhibitors in MF	14:20 – 14:40	Pathogenomes in MDS
09:40 – 10:00	Current treatment of PV	14:40 – 15:00	WHO recommendations 2014
10:00 – 10:20	Treatment of infrequent MPNs	15:00 – 15:20	Supportive care in MDS - what does it mean?
10:20 – 10:40	JAK inhibition in the transplantation setting	15:20 – 15:40	Targeted therapy in MDS
10:40 – 11:00	Break and poster viewing	15:40 – 16:00	Selection of patients for SCT in MDS
	SESSION 2, MEET-THE-SPEAKERS – MPN	16:00 – 16:30	Break and poster viewing
11:00 – 12:00	Parallel meet-the-speaker sessions		SESSION 5, MEET-THE-SPEAKERS – MDS
12:00 – 13:00	Lunch and poster viewing	16:30 – 17:30	Parallel meet-the-speaker sessions
		19:15 – 22:00	Conference dinner

Sunday, 19th October 2014

SESSION 1, POSTER ORAL PRESENTATIONS

08:30 – 10:00 Parallel poster presentations of best abstracts
(CML, MPN, AML, MDS)

10:00 – 10:20 Break and poster viewing

SESSION 2, PLENARY – CASE DISCUSSIONS

10:20 – 11:20 Re-evaluation and discussion of selected case
presentations (CML, MPN, AML, MDS)

11:20 – 11:30 Break and poster viewing

SESSION 3, PLENARY

11:30 – 11:50 CML: Practice vs research

11:50 – 12:10 Newer drugs for the MPNs

12:10 – 12:30 Immunotherapy in AML

12:30 – 12:50 Future diagnostics in MDS – morphology vs molecular

12:50 – 13:00 Meeting wrap-up and close

13:00 – 14:00 Lunch



FACULTY

Michele Baccarani

University of Bologna, Italy

Tiziano Barbui

Ospedale Papa Giovanni XXIII,
Bergamo, Italy

John M. Bennett

University of Rochester Medical
Center, USA

Massimo Breccia

University La Sapienza, Rome, Italy

Dimitri A. Breems

Hospital Network Antwerp, Belgium

Alan K. Burnett

Cardiff University School of
Medicine, United Kingdom

Fausto Castagnetti

University of Bologna, Italy

Mario Cazzola

University of Pavia, Italy

Jaroslav Čermák

Institute of Hematology & Blood
Transfusion, Prague, Czech Republic

Francisco Cervantes

Hospital Clinic Barcelona, Spain

Stefan Constantinescu

Ludwig Institute for Cancer
Research, Brussels, Belgium

Nick C.P. Cross

University of Southampton,
Salisbury, United Kingdom

Arnold Ganser

Hannover Medical School, Germany

Aristoteles Giagounidis

Marien Hospital Düsseldorf,
Germany

Paola Guglielmelli

University of Florence, Italy

François Guilhot

University Hospital of Poitiers,
France

Claire N. Harrison

Guy's and St Thomas' NHS
Foundation Trust, London, United
Kingdom

Rüdiger Hehlmann

Universitätsmedizin Mannheim,
Germany

Juan Carlos Hernández-Boluda

Hospital Clinico Universitario de
Valencia, Spain

Andreas Hochhaus

University Medical Center Jena,
Germany

Wolf-Karsten Hofmann

Universitätsmedizin Mannheim,
Germany

Martin Jädersten

Karolinska Institutet, Stockholm,
Sweden

Joop H. Jansen

Radboud University Nijmegen
Medical Center, The Netherlands

Jean-Jacques Kiladjian

Hôpital Saint-Louis et Université
Paris Diderot, France

Nicolaus Kröger

University Hospital Hamburg,
Germany

Sören Lehman

Karolinska Institutet, Stockholm,
Sweden

Eva Lengfelder

Universitätsmedizin Mannheim,
Germany

Alan F. List

Moffitt Cancer Center, Florida, USA

Michael Lübbert

University of Freiburg, Germany

François-Xavier Mahon

University Hospital of Bordeaux,
France

Maximilian Mossner

Universitätsmedizin Mannheim,
Germany

Martin C. Müller

Universitätsmedizin Mannheim,
Germany

Florian Nolte

Universitätsmedizin Mannheim,
Germany

Daniel Nowak

Universitätsmedizin Mannheim,
Germany

Gert J. Ossenkoppele

VU University Medical Center,
Amsterdam, The Netherlands

Francesca Palandri

University of Bologna, Italy

Fabrizio Pane

University of Naples Federico II, Italy

Francesco Passamonti

University Hospital Varese, Italy

Uwe Platzbecker

University Hospital "Carl Gustav
Carus", Dresden, Germany

Kimmo Porkka

Helsinki University Central Hospital,
Finland

Delphine Réa

Hôpital Saint-Louis, Paris, France

Andreas Reiter

Universitätsmedizin Mannheim,
Germany

Gianantonio Rosti

University of Bologna, Italy

Elisa Rumi

University of Pavia, Italy

Giuseppe Saglio

University of Turin, Italy

Valeria Santini

University of Florence, Italy

Miguel A. Sanz

University Hospital La Fe, Spain

Susanne Sauße

Universitätsmedizin Mannheim,
Germany

Richard Schlenk

University Hospital of Ulm, Germany

Bengt Simonsson

University Hospital Uppsala,
Sweden

Simona Soverini

University of Bologna, Italy

Juan Luis Steegmann

Hospital Universitario de la
Princesa, Madrid, Spain

Rainer Storb

Fred Hutchinson Cancer Research
Center, Seattle, USA

Arjan A. Van de Loosdrecht

VU University Medical Center,
Amsterdam, The Netherlands

Richard A. Van Etten

University of California, USA

Alessandro M. Vannucchi

University of Florence, Italy

Marielle Wondergem

VU University Medical Center,
Amsterdam, The Netherlands

STATEMENTS

Target audience

The programme is designed for haematologists, oncologists and other healthcare professionals who are involved in the treatment of patients with myeloid neoplasias: Chronic myeloid leukaemia (CML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and acute myeloid leukaemia (AML).

Programme goal

The ELN Frontiers Meeting 2014 will provide a state-of-the-art update on current developments in the understanding of disease biology, diagnosis, treatment and management of CML, MDS, MPN, and AML. It will encourage valuable discourse on the pressing problems in those fields.

Learning objectives

- » Understand the molecular mechanisms of myeloid neoplasias
- » Analyse currently available treatment options and factors influencing treatment response in CML, MPN, AML and MDS
- » Discuss the latest clinical trial data on diagnosis and treatment in myeloid neoplasias
- » Learn about epigenetic treatment modalities in AML and MDS patients
- » Discuss the right patient profile for targeted therapy and stem cell transplantation
- » Experience decision making based on clinical cases

CPD/CME accreditation

An application for CPD/CME accreditation of this educational programme will be submitted to the Federation of the Royal Colleges of Physicians of the United Kingdom and the European Accreditation Council for Continuing Medical Education (EACCME) which is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

Financial relationships and off-label/ investigational uses of drugs:

The relevant financial relationships of those persons in a position to control the content of this activity will be disclosed prior to the start of the educational activity. Participants are advised that this activity will contain references to unlabelled/unapproved/investigational uses of drugs.



This activity is an official meeting of the ELN



Endorsed by EUTOS for CML

EUTOS for CML



Supported by an unrestricted
educational grant from Novartis



Co-sponsored by the
University of Heidelberg



Scientific Programme Coordinator

